Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

NCT03573700 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia, Refractory

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna
DEVICE: CliniMACS
BIOLOGICAL: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)

Sponsor

St. Jude Children's Research Hospital